Faculty

Institution

Unit

Venue

Chitra Hosing

Professor

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Breast Surgical Oncology

Division Of Cancer Medicine

Department Of Stem Cell Transplantation

The University of Texas MD Anderson Cancer Center

Chitra Hosing is a Professor at The University of Texas MD Anderson Cancer Center. A senior specialist in hematology and oncology, her research focuses on clinical stem cell and bone marrow transplantation, cellular therapy, and transplantation medicine. Her recent work investigates CAR-T consolidation regimens for large B-cell lymphoma and donor selection priorities for post-transplant cyclophosphamide, alongside analyses of long-term survivor symptom burdens in allogeneic hematopoietic cell transplantation.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Chitra Hosing

The University of Texas MD Anderson Cancer Center

Professor

You can click a keyword to filter the displayed items

hematology medicine cell transplantation oncology immunology clinical transplantation stem cell transplantation transplantation medicine bone marrow transplantation organ transplantation regenerative medicine cellular therapy hematological malignancies cell therapy pharmacology lymphoid neoplasia dermatology leukemia cancer treatment medicinal research cancer research cancer care stem cells outcomes research immunotherapy multiple myeloma laboratory medicine pharmacotherapy stem-cell therapy graft survival stem cell research cord blood transplant surgery graft rejection hemostasis liver transplantation myeloid neoplasia transplant infectious diseases experimental medicine transplantation proceeding clinical immunology cancer management cancer cells cell replacement therapies clinical mycology hla typing cancer biology acute myeloid leukemia myelodysplastic syndrome older patients high-dose chemotherapy medical virology stem cell mobilization malignant blood disorders tissue transplantation blood transfusion risk factors histocompatibility acute lymphoblastic leukemia therapeutic efficacy reduced-intensity conditioning clinical evidence prognostic factors immunohaematology chronic lymphocytic leukemia graft-versus-host disease phase ii study antiviral therapy combined modality treatment post-transplantation cyclophosphamide haploidentical transplantation clinical infectious disease long-term outcomes benchmark studies adaptive immune system cord blood transplantation

Notable Scholarly Works

Notable Federal Grants

Collaborators

Donor Characteristics Significantly Impact the Composition of Peripheral Blood Stem Cell Grafts. Transplantation and Cellular Therapy (2026)

clinical transplantationgraft rejectionorgan transplantationstem cell transplantationcell transplantationimmunologystem cell researchbone marrow transplantationgraft survivalhematologybiomedical engineeringstem cells

Impact of Allogeneic Stem Cell Transplantation in Patients With Higher Risk Myelodysplastic Syndromes. Blood Cancer Journal (2026)

medicineclinical transplantationstem cell transplantationcell transplantationleukemiabone marrow transplantationhematologystem cellsbone marrow failure

Malignant Hematological Diseases: Hyperleukocytosis. (2026)

pathologymalignant blood disordershaematopoiesismalignant hematological diseaseslaboratory hematologyleukemiablood purificationhematologyblood cells

Persistent Symptom Burden and Unmet Needs in Long-Term Survivors of Allogeneic Hematopoietic Cell Transplantation: An Analysis Using the MD Anderson Symptom Inventory (Mdasi-Bmt). Transplantation and Cellular Therapy (2026)

medicinecritical carelong-term survivorsorgan transplantationstem cell transplantationtransplantation medicinecell transplantationpersistent symptom burdensymptom managementbone marrow transplantationunmet needshematology

Re-Evaluating Donor Selection Priorities for Hematopoietic Cell Transplantation With Post-Transplant Cyclophosphamide. JCO Oncology Practice (2026)

medicineclinical transplantationhaematopoiesisorgan transplantationstem cell transplantationtransplantation medicinecell transplantationhematopoietic cell transplantationpost-transplant cyclophosphamideimmunologybone marrow transplantationgraft survivalhematology

Salvage High-Dose Chemotherapy and Autologous Stem Cell Transplant Consolidation Following Relapse After Car-T Cell for Large B-Cell Lymphoma. Haematologica (2026)

cancer immunotherapylarge b-cell lymphomalymphoid neoplasiaoncologystem cell transplantationcell transplantationradiation oncologyleukemiacellular therapyimmunotherapycell therapybone marrow transplantationcar-t cellhematologysalvage high-dose chemotherapy

1057 Early Targeted Biologics Are Associated With Improved Clinical Outcomes in Immune-Related Myocarditis, Myositis, and Myasthenia Gravis. Regular and Young Investigator Award Abstracts (2025)

immune-related myocarditismedicineimmune responsesinflammationimmunologic diseasesimproved clinical outcomesmyasthenia gravisautoimmune diseasesimmunologyimmunotherapymyositisrheumatismclinical rheumatologyinflammatory diseasesautoimmunity

A Phase II Trial of Azacitidine With Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab in Previously Untreated Myelodysplastic Syndrome. Haematologica (2025)

pharmacologyclinical trialsmedicinephase ii trialpharmacotherapymyeloid neoplasiahematologymyelodysplastic syndrome

Author Correction: Allogeneic Nk Cells With a Bispecific Innate Cell Engager in Refractory Relapsed Lymphoma: A Phase 1 Trial. Nature Medicine (2025)

pathologyphase 1cancer cellslymphoid neoplasiaoncologycell transplantationleukemiacellular therapyallogeneic nk cellsimmunotherapyimmunologyadult t-cell leukemia-lymphomaimmune responsesauthor correction

Cd34+/Tnc Ratio Predicts Relapse in Aml/Mds Patients Receiving Peripheral Blood Matched Allogeneic Stem Cell Transplantation With Post-Transplant Cyclophosphamide. Blood (2025)

aml/mds patientspathologyperipheral bloodcd34+/tnc ratiomedicinehaematopoiesisstem cell transplantationcell transplantationleukemiacell therapybone marrow transplantationhematologycell replacement therapies

1
2
3
4
5
74
10 / page

Chitra Hosing

Professor

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Breast Surgical Oncology

Division Of Cancer Medicine

Department Of Stem Cell Transplantation

The University of Texas MD Anderson Cancer Center

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Chitra Hosing

The University of Texas MD Anderson Cancer Center

Professor

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Donor Characteristics Significantly Impact the Composition of Peripheral Blood Stem Cell Grafts. Transplantation and Cellular Therapy (2026)

Impact of Allogeneic Stem Cell Transplantation in Patients With Higher Risk Myelodysplastic Syndromes. Blood Cancer Journal (2026)

medicineclinical transplantationstem cell transplantationcell transplantationleukemiabone marrow transplantationhematologystem cellsbone marrow failure

Malignant Hematological Diseases: Hyperleukocytosis. (2026)

pathologymalignant blood disordershaematopoiesismalignant hematological diseaseslaboratory hematologyleukemiablood purificationhematologyblood cells

Re-Evaluating Donor Selection Priorities for Hematopoietic Cell Transplantation With Post-Transplant Cyclophosphamide. JCO Oncology Practice (2026)

Salvage High-Dose Chemotherapy and Autologous Stem Cell Transplant Consolidation Following Relapse After Car-T Cell for Large B-Cell Lymphoma. Haematologica (2026)

1057 Early Targeted Biologics Are Associated With Improved Clinical Outcomes in Immune-Related Myocarditis, Myositis, and Myasthenia Gravis. Regular and Young Investigator Award Abstracts (2025)

A Phase II Trial of Azacitidine With Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab in Previously Untreated Myelodysplastic Syndrome. Haematologica (2025)

pharmacologyclinical trialsmedicinephase ii trialpharmacotherapymyeloid neoplasiahematologymyelodysplastic syndrome

Author Correction: Allogeneic Nk Cells With a Bispecific Innate Cell Engager in Refractory Relapsed Lymphoma: A Phase 1 Trial. Nature Medicine (2025)

Cd34+/Tnc Ratio Predicts Relapse in Aml/Mds Patients Receiving Peripheral Blood Matched Allogeneic Stem Cell Transplantation With Post-Transplant Cyclophosphamide. Blood (2025)

1
2
3
4
5
74
10 / page